Biography:

Guy H Fontaine has made 17 original contributions in the design and the use of the first cardiac pace makers in the early 60s. He has serendipitously identified ARVD during his contributions to antiarrhythmic surgery in the early 70s. He has developed the technique of Fulguration to replace surgery in the early 80s (technique used during 30 years in Paris). He has been one of the 216 individuals who have made a significant contribution to the study of cardiovascular disease since the 14th century, one of the 500 greatest geniuses of the 21th Century (USA Books), one of the 100 Life Time Achievement (UK Book). He has more than 900 publications including 201 chapters in text books.

He is the reviewer of 26 scientific journals both in basic and clinical science. He served as a member of the Editorial Board of Circulation for 5 years, after reviewing articles for this journal during decades. He has given 11 master lectures of 90 minutes each in inland China in 2014. He has recently developed new techniques of hypothermia for brain protection in OHCA and Stroke. This technique has been fortuitously used after resuscitation of his wife at home in June 2011 with absolutely no neurologic deficit despite 6 minutes of no flow. He has also invented a high-tech device which can be considered the ultimate in palliative care by preventing unexpectedly awaking after ordinary sleep. This device was mostly designed for major neurologic disorders. To know more about him introduce his full name on Google “Guy Hugues Fontaine”. His main lectures for the year 2016 have been in Cardiology and Neurology in: London, Dubai, Berlin, Baltimore, Philadelphia, Las Vegas, Tucson, Miami and Dubai again.

Abstract:

Atrial fibrillation is the most common arrhythmia in human. It is a cause of mortality and morbidity leading to one of the most important expenditure in the modern world. Especially, it is increasing even further because of prolongation of life due to the advances of medicine. A group from Paris has attempted to demonstrate a link between fat in the epicardium of atrial tissue to the production of fibrosis as a possible mechanism of atrial fibrillation (AF) [1]. In their discussion and conclusion the authors admit that the mechanism of AF is not completely understood. After an excellent review of the CMR techniques available for the identification of fat, fibrosis and water in the heart, they note a lack of spatial resolution of modern imaging techniques that result in their performing ex vivo CMR on two hearts. However, the modern digital microscope has an optimal resolution which could enable a more precise interpretation of the pathophysiology of AF.

The knowledge accumulated from my study of the histology of ARVD of the right ventricle from 73 patients clearly shows the topographic structure of fat, fibrosis and possible superimposed myocarditis. The atrial structure of the so-called “normal heart” is similar to that observed on the free wall of the right ventricle in ARVD. In addition to epicardial fat, there is fibrosis of two forms, interstitial fibrosis which can be the result of the genetic disorder of the disease or, replacement fibrosis which may be the result of myocarditis generally starting from the epicardium (epicardial-myocarditis as it is known by clinicians).  A superimposed myocarditis may have a spectrum of presentation from the fulminant form leading to acute heart failure and death in a few days associated with invasion of both ventricles and atria by lymphocytes to that of a completely healed hyaline fibrosis. There may be intermediate aspects of myocarditis with a variable number of clusters of lymphocytes inside strands of fibrosis called the chronic-active form [2]. Also, there may be a genetic factor now considered to be of increasing importance in the understanding of ventricular cardiomyopathies [3,4]. In the background of atrial fibrillation [5] these cardiomyopathies can be present but quiescent without arrhythmias in the general population [6]. There can be additional complexity if we consider that myocarditis alone can cause fibrosis and adipocytes [2]. Therefore, myocarditis can produce an arrhythmogenic substrate. In addition, the acute form can be a trigger of arrhythmias associated with an increase of CRP [7]. The same gene that is responsible for the problem in atrial development can also explain the increased susceptibility of these hearts [8] to be affected by myocarditis in a single or in multiple episodes by entero and adeno viruses [9, 10]. Therefore, the prevention or treatment of lone atrial fibrillation may be due to two targets: protection against and/or suppression of viruses [11], and prevention of fibrosis [12]. In the future, the ideal approach to prevention of atrial fibrillation will be the modification of the human genome using the genetic approaches such as the CRISPRcas9 [13]. Finally, the results obtained in the treatment of atrial fibrillation may be expanded to the treatment of the whole heart since the atrium and ventricle are two parts of the same embryologic structure as has been recently confirmed by the finding of “atrial dysplasia” [14]. A simple new tool to evaluate patients at risk of atrial fibrillation and to follow the effect of treatment should be the use of the new 16 lead High Definition ECG recorder [6].